Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes

Abstract Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment. However, the objective response rates (ORR) are relatively low due to the lack of precise biomarkers to select patients. Herein, the molecular subtype, tumor mutation burden...

Descrición completa

Detalles Bibliográficos

Principais autores:	Zihao Chen, Guojun Liu, Guoqing Liu, Mikhail A. Bolkov, Khyber Shinwari, Irina A. Tuzankina, Valery A. Chereshnev, Zhifeng Wang
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2021-01-01
Series:	Hereditas
Assuntos:	TMB CD8+ T cells Molecular subtype Immunotherapy MIBC Immunotype
Acceso en liña:	https://doi.org/10.1186/s41065-020-00165-7
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!